Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Nick J
Mucosal autoimmune disorders represent a complex and enigmatic group of diseases that afflict various mucosal surfaces within the human body, including the gastrointestinal tract, oral cavity, and respiratory system. These conditions, such as Crohn’s disease, ulcerative colitis, celiac disease, and oral lichen planus, share a common feature the immune system’s misguided attack on its own tissues, leading to chronic inflammation and tissue damage. This abstract provides an overview of the current state of knowledge regarding mucosal autoimmune disorders, with a focus on recent advancements in understanding their etiology, pathogenesis, and potential therapeutic strategies. Deciphering the code of mucosal autoimmune disorders involves unraveling the intricate interplay of genetic susceptibility, environmental triggers, and dysregulated immune responses. Genetic studies have identified numerous susceptibility loci associated with these conditions, shedding light on the genetic underpinnings of mucosal autoimmunity. Environmental factors, including diet, microbiota composition, and exposure to pathogens, have also been implicated in disease initiation and progression. The immune system’s role in mucosal autoimmunity is multifaceted, with both innate and adaptive immunity playing pivotal roles. Dysregulation of immune checkpoints, cytokine signaling pathways, and the gut-associated lymphoid tissue contributes to the perpetuation of chronic inflammation and tissue damage. Understanding these immune mechanisms is crucial for the development of targeted therapies. Recent advancements in the field of mucosal autoimmune disorders have brought forth promising therapeutic avenues. Biologic agents targeting specific immune pathways, such as anti-TNF-alpha and anti-IL-23 agents, have shown efficacy in managing diseases like Crohn’s disease and ulcerative colitis. Additionally, personalized medicine approaches, guided by genetic and immunological profiling, hold potential for tailoring treatments to individual patients.